Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDS 0101

Drug Profile

PDS 0101

Alternative Names: PDS 101; PDS-0101; PDS-0101C; PDS0101A; PDS0101B; Versamune-HPV; Versamune®-HPV16

Latest Information Update: 17 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDS Biotechnology Corporation
  • Developer Merck & Co; National Cancer Institute (USA); PDS Biotechnology Corporation
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants; Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Anal cancer; Anal intraepithelial neoplasia; Cancer; Cervical cancer; Cervical intraepithelial neoplasia; Head and neck cancer; Oropharyngeal cancer; Penile cancer; Rectal cancer; Squamous cell cancer; Vulvovaginal cancer

Most Recent Events

  • 14 Nov 2023 PDS Biotech plans the registrational phase III VERSATILE-003 trial in Head and neck cancer (Combination therapy, Metastatic disease, Inoperable/Unresectable, Recurrent), in the first quarter of 2024
  • 20 Oct 2023 Efficacy data from the phase II VERSATILE-002 trial in Head and neck cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 03 Oct 2023 Updated efficacy and adverse events data from the phase II VERSATILE-002 trial in Squamous cell cancer released by PDS Biotechnology Corporation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top